PIL
25/05/2015 09:47
GENERAL
PRICE SENSITIVE
REL: 0947 HRS Promisia Integrative Limited
GENERAL: PIL: Positive preliminary findings - clinical trial of Arthrem
25 May 2015
Positive preliminary findings from a clinical trial of Arthrem(TM)
Mr Malcolm Johnson, Chairman of Promisia Integrative Limited, announced today
positive and statistically significant preliminary results from a clinical
trial of Arthrem(TM), a dietary supplement for joint support.
The randomised, double-blind, placebo-controlled, 12 week trial was conducted
by the Rheumatology Research Unit at the University of Otago and was
partially funded by Callaghan Innovation. Preliminary results show that
supplementation with Arthrem(TM) (1 capsule twice daily) provided significant
benefits for research participants aged 35-75 with hip or knee
osteoarthritis.
Promisia's Principal Scientist Dr Sheena Hunt explained: "Osteoarthritis
symptoms were evaluated using the Western Ontario and McMaster Universities
Arthritis (WOMAC) Index, a widely used proprietary set of standardised
questionnaires. Participants' pain was assessed by a visual analogue scale."
Dr Hunt continued: "Over the 12 week study, the reduction in average pain
score in the Arthrem(TM) group was statistically significant compared to
baseline. Improvements in average WOMAC scores for physical function and
stiffness were also statistically significant compared to baseline. There
were no statistically significant improvements in the placebo group for any
parameter. Arthrem(TM) at a dose of 1 capsule twice daily was also safe and
well tolerated by study participants."
Chief executive officer Mr Charles Daily said: "We are delighted with these
preliminary results from our first clinical trial. There is no requirement
in New Zealand to prove the safety and/or efficacy of dietary supplements;
however, we believe it is important to conduct robust scientific research in
order to allow consumers to make informed decisions when buying a dietary
supplement for joint support."
It is intended that the full results will be published in a scientific,
peer-reviewed journal.
For further information please contact:
Mr Charles Daily, Chief Executive Officer on 04 894 8524 or 021 643 906
ENDS
End CA:00264745 For:PIL Type:GENERAL Time:2015-05-25 09:47:22
